Cyclopamine and Jervine in Embryonic Rat Tongue Cultures Demonstrate A
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Cyclopamine Inhibition of Sonic Hedgehog Signal Transduction Is
Developmental Biology 224, 440–452 (2000) doi:10.1006/dbio.2000.9775, available online at http://www.idealibrary.com on View metadata, citation and similar papers at core.ac.uk brought to you by CORE Cyclopamine Inhibition of Sonic Hedgehog Signalprovided by Elsevier - Publisher Connector Transduction Is Not Mediated through Effects on Cholesterol Transport John P. Incardona,* William Gaffield,† Yvonne Lange,‡ Adele Cooney,§ Peter G. Pentchev,§ Sharon Liu,¶ John A. Watson,¶ Raj P. Kapur,ሻ and Henk Roelink*,1 *Department of Biological Structure and Center for Developmental Biology and Department of Pathology, University of Washington, Seattle, Washington 98195; †Western Regional Research Center, ARS, United States Department of Agriculture, Albany, California 94710; ‡Department of Pathology, Rush–Presbyterian–St. Luke’s Medical Center, Chicago, Illinois 60612; §Developmental and Metabolic Neurobiology Branch, NINDS, National Institutes of Health, Bethesda, Maryland 20892; and ¶Department of Biochemistry and Biophysics, University of California at San Francisco, San Francisco, California 94143 Cyclopamine is a teratogenic steroidal alkaloid that causes cyclopia by blocking Sonic hedgehog (Shh) signal transduction. We have tested whether this activity of cyclopamine is related to disruption of cellular cholesterol transport and putative secondary effects on the Shh receptor, Patched (Ptc). First, we report that the potent antagonism of Shh signaling by cyclopamine is not a general property of steroidal alkaloids with similar structure. The structural features of steroidal alkaloids previously associated with the induction of holoprosencephaly in whole animals are also associated with inhibition of Shh signaling in vitro. Second, by comparing the effects of cyclopamine on Shh signaling with those of compounds known to block cholesterol transport, we show that the action of cyclopamine cannot be explained by inhibition of intracellular cholesterol transport. -
Coincident Two Mutations and One Single Nucleotide Polymorphism of the PTCH1 Gene in a Family with Naevoid Basal Cell Carcinoma Syndrome
Letters to the Editor 635 Coincident Two Mutations and One Single Nucleotide Polymorphism of the PTCH1 Gene in a Family with Naevoid Basal Cell Carcinoma Syndrome Shoko Abe1, Kenji Kabashima1*, Jun-ichi Sakabe1, Takatoshi Shimauchi1, Zhang Yan2, Tetsuji Okamoto2 and Yoshiki Tokura1 1Department of Dermatology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, and 2Department of Molecular Oral Medicine and Maxillofacial Surgery 1, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. E-mail: [email protected] Accepted May 7, 2008. Sir, at nucleotide position 667 within exon 3 and an intervening se- Naevoid basal cell carcinoma syndrome (NBCCS, OMIM quence (IVS)16 -3T > C, and a SNP; IVS10 -8T > C, were detected in all three cases. A deletion of AGAC causes a frameshift and a #109400), also called Gorlin’s syndrome, is an autosomal subsequent stop codon in exon 3, which prematurely truncates dominant disease that affects about 1 in 60,000 indivi- the protein (Fig. 1a). In addition, the IVS16 -3T > C could lead duals (1, 2). NBCCS is associated with various skeletal to an aberrant splicing and truncation of PTCH1 (10–12). and neurocutaneous abnormalities. Major manifestations To detect the expression level of PTCH1 protein in the skin, are multiple basal cell carcinomas (BCCs), odontogenic an immunohistochemical study was performed using goat poly- clonal anti-PTCH1 antibody (G-19; Santa Cruz Biotechnology, keratocysts, palmoplantar dyskeratotic pits and intra- Santa Cruz, CA, USA). Enzyme reactions were developed with cranial calcification (3). In addition, rib and vertebral conventional substrates for diamino-benzidine (Sigma, St Louis, malformations, epidermal cysts, macrocephaly, facial MO, USA) (13). -
Review of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics
cancers Review Review of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics James M. Kilgour , Justin L. Jia and Kavita Y. Sarin * Department of Dermatology, Stanford University School of Medcine, Stanford, CA 94305, USA; [email protected] (J.M.K.); [email protected] (J.L.J.) * Correspondence: [email protected] Simple Summary: Basal cell carcinoma is the most common human cancer worldwide. The molec- ular basis of BCC involves an interplay of inherited genetic susceptibility and somatic mutations, commonly induced by exposure to UV radiation. In this review, we outline the currently known germline and somatic mutations implicated in the pathogenesis of BCC with particular attention paid toward affected molecular pathways. We also discuss polymorphisms and associated phenotypic traits in addition to active areas of BCC research. We finally provide a brief overview of existing non-surgical treatments and emerging targeted therapeutics for BCC such as Hedgehog pathway inhibitors, immune modulators, and histone deacetylase inhibitors. Abstract: Basal cell carcinoma (BCC) is a significant public health concern, with more than 3 million cases occurring each year in the United States, and with an increasing incidence. The molecular basis of BCC is complex, involving an interplay of inherited genetic susceptibility, including single Citation: Kilgour, J.M.; Jia, J.L.; Sarin, nucleotide polymorphisms and genetic syndromes, and sporadic somatic mutations, often induced K.Y. Review of the Molecular Genetics of Basal Cell Carcinoma; by carcinogenic exposure to UV radiation. This review outlines the currently known germline and Inherited Susceptibility, Somatic somatic mutations implicated in the pathogenesis of BCC, including the key molecular pathways Mutations, and Targeted affected by these mutations, which drive oncogenesis. -
Sonidegib for the Treatment of Advanced Basal Cell Carcinoma
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Sonidegib for the treatment of advanced basal cell carcinoma Ramelyte, Egle ; Amann, Valerie C ; Dummer, Reinhard DOI: https://doi.org/10.1080/14656566.2016.1225725 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-125862 Journal Article Accepted Version Originally published at: Ramelyte, Egle; Amann, Valerie C; Dummer, Reinhard (2016). Sonidegib for the treatment of advanced basal cell carcinoma. Expert Opinion on Pharmacotherapy, 17(14):1963-1968. DOI: https://doi.org/10.1080/14656566.2016.1225725 Sonidegib for the treatment of advanced basal cell carcinoma Egle Ramelyte1,2,MD, Valerie C. Amann1, MD, Reinhard Dummer 1, MD, 1 - Department of Dermatology, University Hospital Zurich, Zurich, Switzerland 2 - Vilnius University, Centre of Dermatovenereology, Vilnius, Lithuania Corresponding author: Reinhard Dummer, MD University Hospital of Zurich Department of Dermatology Gloriastrasse 31 CH-8091, Zürich, Switzerland Phone: 41-44-255-2507 Fax: 41-44-255-8988 E-mail: [email protected] 1 Abstract Introduction. Advanced and metastatic basal cell carcinomas (BCCs) are rare but still present a severe medical problem. These tumors are often disfiguring and impact the quality of life by pain or bleeding. Based on discovery of the hedgehog (Hh) signaling pathway and it’s role in pathogenesis of BCCs, Smoothened (SMO) inhibitors have been developed with Sonidegib being the 2nd in class. It is the only Hh pathway inhibitor investigated in a randomized trial accompanied by pharmacodynamic investigations. Also, the disease assessment criteria applied were more stringent than those used in trials of 1st developed SMO inhibitor – vismodegib, and required annotated photographs, MRI as well as multiple biopsies in case of regression. -
The Cell Adhesion Molecule CHL1 Interacts with Patched-1 to Regulate
© 2017. Published by The Company of Biologists Ltd | Journal of Cell Science (2017) 130, 2606-2619 doi:10.1242/jcs.194563 RESEARCH ARTICLE The cell adhesion molecule CHL1 interacts with patched-1 to regulate apoptosis during postnatal cerebellar development Jelena Katic1, Gabriele Loers1, Jelena Tosic1, Melitta Schachner2,3,4,* and Ralf Kleene1 ABSTRACT differentiated neural cells (Holm et al., 1996; Chen et al., 1999; The immunoglobulin superfamily adhesion molecule close homolog of Hillenbrand et al., 1999; Buhusi et al., 2003; Jakovcevski et al., L1 (CHL1) plays important roles during nervous system development. 2007, 2009; Katic et al., 2014). Moreover, CHL1 regulates Here, we identified the hedgehog receptor patched-1 (PTCH1) as a neuritogenesis through different mechanisms (Chen et al., 1999; novel CHL1-binding protein and showed that CHL1 interacts with Hillenbrand et al., 1999; Jakovcevski et al., 2007, 2009; Katic et al., the first extracellular loop of PTCH1 via its extracellular domain. 2014). In search for novel binding partners for CHL1, we found that trans Colocalization and co-immunoprecipitation of CHL1 with PTCH1 PTCH1 and CHL1 associate in a heterophilic -interaction. The suggest an association of CHL1 with this major component of the 12-pass transmembrane protein PTCH1 is a cognate receptor for the hedgehog signaling pathway. The trans-interaction of CHL1 with PTCH1 three mammalian hedgehog family members sonic hedgehog promotes neuronal survival in cultures of dissociated cerebellar granule (SHH), desert hedgehog (DHH) and indian hedgehog (IHH), cells and of organotypic cerebellar slices. An inhibitor of the PTCH1- which act as morphogens and function as signaling molecules by regulated hedgehog signal transducer, smoothened (SMO), and binding to PTCH1 (for reviews and references therein, see Jenkins, inhibitors of RhoA and Rho-associated kinase (ROCK) 1 and 2 2009; Robbins et al., 2012; Briscoe and Thérond, 2013). -
A New Trick for an Old Lipid Cholesterol Can Regulate the Hedgehog Signalling Pathway by Directly Binding to a Receptor on the Cell Surface
INSIGHT SIGNALLING A new trick for an old lipid Cholesterol can regulate the Hedgehog signalling pathway by directly binding to a receptor on the cell surface. HAYLEY SHARPE Hedgehog, a transmembrane protein called Related research article Luchetti G, Sircar Patched, and a transmembrane receptor protein R, Kong JH, Nachtergaele S, Sagner A, called Smoothened. In the absence of Hedge- Byrne EFX, Covey DF, Siebold C, Rohatgi R. hog, Patched inhibits Smoothened. However, when Hedgehog binds to Patched, this inhibi- 2016. Cholesterol activates the G-protein tion is blocked and Smoothened is able to acti- coupled receptor Smoothened to promote vate other Hedgehog pathway components morphogenetic signaling. eLife 5:e20304. inside the cell. It is thought that Patched and doi: 10.7554/eLife.20304 Smoothened communicate using a small mole- cule rather than by direct contact (Taipale et al., 2002), but it is not clear exactly how this works. Smoothened possesses two sites at which holesterol is a lipid molecule that is a small molecules are able to bind: one is in its vital component of all animal cell mem- transmembrane domain region and the other is C branes. It provides structural integrity, in its cysteine-rich domain on the external sur- which is needed for the membrane to be an face of the cell. A similar cysteine-rich domain is effective barrier, and is also required for the pro- found in several other proteins, where it is duction of hormones and vitamin D. These roles known to be able to bind to lipids (Bazan et al., mean the production and transport of choles- 2009). -
Underestimated PTCH1 Mutation Rate in Sporadic Keratocystic Odontogenic Tumors Q
Oral Oncology 51 (2015) 40–45 Contents lists available at ScienceDirect Oral Oncology journal homepage: www.elsevier.com/locate/oraloncology Underestimated PTCH1 mutation rate in sporadic keratocystic odontogenic tumors q Jiafei Qu a, Feiyan Yu a, Yingying Hong a, Yanyan Guo a, Lisha Sun b, Xuefen Li b, Jianyun Zhang a, ⇑ ⇑ Heyu Zhang b, Ruirui Shi b, Feng Chen b, , Tiejun Li a, a Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing, China b Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, China article info summary Article history: Objectives: Keratocystic odontogenic tumors (KCOTs) are benign cystic lesions of the jaws that occur spo- Received 11 July 2014 radically in isolation or in association with nevoid basal cell carcinoma syndrome (NBCCS). The protein Received in revised form 29 August 2014 patched homolog 1 gene (PTCH1) is associated with NBCCS development and tumor genesis associated Accepted 26 September 2014 with this syndrome. However, previous studies have revealed that more than 85% of syndromic KCOTs Available online 18 November 2014 and less than 30% of sporadic KCOTs harbor PTCH1 mutations. The significantly lower PTCH1 mutation rates observed in sporadic KCOTs suggest that they serve a minor role in pathogenesis. We aimed to Keywords: discern the importance of PTCH1 mutations in sporadic KCOTs. PTCH1 Materials and methods: PTCH1 mutational analysis was performed with 19 new sporadic KCOT cases by Mutation Keratocystic odontogenic tumors direct sequencing of epithelial lining samples separated from fibrous capsules. Using this approach, we further reexamined 9 sporadic KCOTs that were previously reported to lack PTCH1 mutations by our group. -
Assessment Report
25 June 2015 EMA/472165/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Odomzo International non-proprietary name: sonidegib Procedure No. EMEA/H/C/002839/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure ............................................ 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Manufacturers ...................................................................................................... 8 1.3. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion .............................................................................. 9 2.1. Introduction......................................................................................................... 9 2.2. Quality aspects .................................................................................................. 11 2.2.1. Introduction .................................................................................................... 11 -
Nevoid Basal Cell Carcinoma Syndrome and Non-Hodgkin's
Nevoid Basal Cell Carcinoma Syndrome and Non-Hodgkin’s Lymphoma CPT Beth A. Schulz-Butulis, MC, USAR, Fort Sam Houston, Texas MAJ Robert Gilson, MC, USAF, Fort Sam Houston, Texas MAJ Mary Farley, MC, USAR, Fort Sam Houston, Texas COL James H. Keeling, MC, USA, Fort Sam Houston, Texas Nevoid basal cell carcinoma syndrome (NBCCS) is a hereditary disorder with a predilection for nu- merous basal cell carcinomas in addition to odon- togenic keratocysts, palmoplantar pitting, and skeletal malformations. NBCCS has been associ- ated with a number of benign and malignant neo- plasms. We report the first case of NBCCS in as- sociation with non-Hodgkin’s lymphoma. evoid basal cell carcinoma syndrome (NBCCS), also known as basal cell nevus syn- drome, Gorlin syndrome, Gorlin-Goltz syn- N 1,2 drome, or fifth phacomatosis, is an autosomal dom- inant disease linked to chromosome 9q22.3-q31.3-5 It is a progressive degenerative multisystem disease FIGURE 1. The back of a patient shows multiple basal characterized by a predisposition to develop basal cell cell carcinomas. (Photograph courtesy of MAJ Thomas carcinomas (BCCs) of the skin, palmoplantar pitting, Hirota, MC, USA.) odontogenic keratocysts, bifid ribs, kyphoscoliosis, short fourth metacarpals, ocular abnormalities, calci- the first known report of non-Hodgkin’s lymphoma fied dural folds, endocrine abnormalities, and various associated with NBCCS. internal neoplasms.1,2 Internal neoplasms that have been reported in asso- Case Report ciation with NBCCS include medulloblastoma,6 cran- A 54-year-old white man presented with numerous iopharyngioma,7 meningioma,2 astrocytoma,8 oligo- basal cell cancers. -
Characterization of Two Patched Receptors for the Vertebrate Hedgehog Protein Family
Proc. Natl. Acad. Sci. USA Vol. 95, pp. 13630–13634, November 1998 Cell Biology Characterization of two patched receptors for the vertebrate hedgehog protein family DAVID CARPENTER*, DONNA M. STONE†,JENNIFER BRUSH‡,ANNE RYAN§,MARK ARMANINI†,GRETCHEN FRANTZ§, ARNON ROSENTHAL†, AND FREDERIC J. DE SAUVAGE*¶ Departments of *Molecular Oncology, ‡Molecular Biology, §Pathology, and †Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080 Communicated by David V. Goeddel, Tularik, Inc., South San Francisco, CA, September 24, 1998 (received for review June 12, 1998) ABSTRACT The multitransmembrane protein Patched mammalian hedgehogs or whether ligand-specific components (PTCH) is the receptor for Sonic Hedgehog (Shh), a secreted exist. Interestingly, a second murine PTCH gene, PTCH2, was molecule implicated in the formation of embryonic structures isolated recently (25) but its function as a hedgehog receptor and in tumorigenesis. Current models suggest that binding of has not been established. To characterize PTCH2 and com- Shh to PTCH prevents the normal inhibition of the seven- pare it with PTCH with respect to the biological function of the transmembrane-protein Smoothened (SMO) by PTCH. Ac- various hedgehog family members, we isolated the human cording to this model, the inhibition of SMO signaling is PTCH2 gene. Binding analysis shows that both PTCH and relieved after mutational inactivation of PTCH in the basal PTCH2 bind to all three hedgehog ligands with similar affinity. cell nevus syndrome. Recently, PTCH2, a molecule with Furthermore PTCH2 interacts with SMO, suggesting that it sequence homology to PTCH, has been identified. To charac- can form a functional multicomponent hedgehog receptor terize both PTCH molecules with respect to the various complex similar to PTCH-SMO. -
Australian Public Assessment Report for Odomzo
Australian Public Assessment Report for Odomzo Proprietary Product Name: Sonidegib Sponsor: Novartis Pharmaceuticals Australia Pty Ltd November 2019 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. • An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA. -
Hedgehog Targeting by Cyclopamine Suppresses Head and Neck Squamous Cell Carcinoma and Enhances Chemotherapeutic Effects
ANTICANCER RESEARCH 33: 2415-2424 (2013) Hedgehog Targeting by Cyclopamine Suppresses Head and Neck Squamous Cell Carcinoma and Enhances Chemotherapeutic Effects CHRISTIAN MOZET*, MATTHAEUS STOEHR*, KAMELIA DIMITROVA, ANDREAS DIETZ and GUNNAR WICHMANN Department of Otolaryngology, Head and Neck Surgery, University of Leipzig, Leipzig, Germany Abstract. Background: The hedgehog signaling pathway prognosis is worse for those with metastatic disease (2). (HH) is involved in tumorigenesis in a variety of human Besides known risk factors (e.g. alcohol and smoking) and malignancies. In head and neck squamous cell carcinomas occupational exposure to other poorly understood factors, the (HNSCC), Hh overexpression was associated with poor entirety of the relevant tumor biology is still unclear. prognosis. Therefore, we analyzed the effect of Hh signaling Mortality rates of HNSCC have remained almost unchanged blockade with cyclopamine on colony formation of cells from for decades, even though the detection of tumor-specific HNSCC samples. Patients and Methods: HNSCC biopsies pathways has developed rapidly and offers a number of new were cultured alone for reference or with serial dilutions of targets in tumor therapy regimes (e.g. the epidermal growth cyclopamine (5-5,000 nM), docetaxel (137.5-550 nM), or factor-receptor, EGFR, and its tyrosine kinases). Proven cisplatin (1,667-6,667 nM) and their binary combinations. standardized concepts of tumor therapy in first- or second- Cytokeratin-positive colonies were counted after fluorescent line protocols are combinations of well-established cytostatic staining. Results: Cyclopamine concentration-dependently drugs such as platinum-derivates like cisplatin, taxanes like inhibited HNSCC ex vivo [(IC50) at about 500 nM]. In binary docetaxel or others (e.g.